Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CCCC logo CCCC
Upturn stock ratingUpturn stock rating
CCCC logo

C4 Therapeutics Inc (CCCC)

Upturn stock ratingUpturn stock rating
$1.71
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/08/2025: CCCC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $15.8

1 Year Target Price $15.8

Analysts Price Target For last 52 week
$15.8 Target price
52w Low $1.08
Current$1.71
52w High $7.66

Analysis of Past Performance

Type Stock
Historic Profit -42.3%
Avg. Invested days 20
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/08/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 121.42M USD
Price to earnings Ratio -
1Y Target Price 15.8
Price to earnings Ratio -
1Y Target Price 15.8
Volume (30-day avg) 8
Beta 2.95
52 Weeks Range 1.08 - 7.66
Updated Date 07/8/2025
52 Weeks Range 1.08 - 7.66
Updated Date 07/8/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.48

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -259.6%
Operating Margin (TTM) -402.93%

Management Effectiveness

Return on Assets (TTM) -20.3%
Return on Equity (TTM) -45.55%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -42790234
Price to Sales(TTM) 3.05
Enterprise Value -42790234
Price to Sales(TTM) 3.05
Enterprise Value to Revenue 8.85
Enterprise Value to EBITDA -0.42
Shares Outstanding 71007104
Shares Floating 49730521
Shares Outstanding 71007104
Shares Floating 49730521
Percent Insiders 9.79
Percent Institutions 91.87

ai summary icon Upturn AI SWOT

C4 Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

C4 Therapeutics, Inc. (CCCC) was founded in 2011 and is a biopharmaceutical company focused on discovering and developing targeted protein degradation therapeutics. They aim to create novel therapies for cancer and other diseases. Their approach is centered around utilizing the ubiquitin-proteasome system to selectively degrade disease-causing proteins.

business area logo Core Business Areas

  • Targeted Protein Degradation (TPD): C4 Therapeutics' primary focus is on developing small-molecule drugs that induce the degradation of disease-causing proteins. Their approach is applicable across various therapeutic areas, with a focus on oncology and other diseases.
  • Drug Discovery and Development: The company engages in all stages of drug discovery and development, from target identification and validation to preclinical studies and clinical trials.
  • Collaboration and Partnerships: C4 Therapeutics collaborates with other pharmaceutical companies to expand their pipeline and accelerate drug development.

leadership logo Leadership and Structure

Andrew Hirsch serves as the President and CEO. The organizational structure includes research and development, clinical operations, business development, and corporate functions.

Top Products and Market Share

overview logo Key Offerings

  • CFT7455: An oral MonoDAC degrader of IKZF1/3, is in Phase 1/2 clinical trials for relapsed/refractory multiple myeloma and relapsed/refractory non-Hodgkin lymphoma. No current market share or revenue information is publicly available as it is in clinical development. Competitors in myeloma include companies developing proteasome inhibitors, immunomodulatory drugs, and antibody therapies. Competitors in lymphoma are the many established therapies for lymphoma patients.
  • CFT1946: An oral BiDAC degrader of BRD9, is in Phase 1 clinical trials for SMARCA4-mutant solid tumors, including non-small cell lung cancer. No current market share or revenue information is publicly available as it is in clinical development. Competitors include companies developing SMARCA4 inhibitors and various chemotherapy regimens.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by intense competition, high research and development costs, and lengthy regulatory approval processes. Targeted protein degradation is an emerging field with significant potential to address previously undruggable targets.

Positioning

C4 Therapeutics is positioned as a leader in the targeted protein degradation field, with a proprietary platform and a growing pipeline of drug candidates. Their competitive advantage lies in their expertise in designing and developing degrader molecules.

Total Addressable Market (TAM)

The TAM for targeted protein degradation therapies is potentially very large, addressing various diseases with currently unmet medical needs. The specific TAM for C4 Therapeutics' current pipeline depends on the successful development and approval of their drug candidates. Precise TAM estimates are difficult to provide without specific market forecasts for each indication.

Upturn SWOT Analysis

Strengths

  • Proprietary targeted protein degradation platform
  • Strong scientific expertise and experienced management team
  • Growing pipeline of drug candidates
  • Strategic collaborations with pharmaceutical companies

Weaknesses

  • Early stage of development with limited clinical data
  • High reliance on preclinical data and potential clinical trial risks
  • Significant cash burn and reliance on future funding
  • Competition from other companies in the TPD space

Opportunities

  • Potential to develop first-in-class TPD therapies
  • Expansion of pipeline into new therapeutic areas
  • Strategic partnerships to accelerate drug development
  • Increasing adoption of TPD as a therapeutic modality

Threats

  • Clinical trial failures and regulatory setbacks
  • Competition from established pharmaceutical companies
  • Patent challenges and intellectual property disputes
  • Changes in the regulatory landscape

Competitors and Market Share

competitor logo Key Competitors

  • KYMR
  • ARRY

Competitive Landscape

C4 Therapeutics' competitive advantage lies in its specific TPD platform. However, it faces competition from companies with established pipelines and greater financial resources.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been driven by preclinical progress and strategic partnerships.

Future Projections: Future growth depends on the successful development and commercialization of its drug candidates. Analyst estimates can be found on financial websites, but are subject to change based on clinical trial outcomes.

Recent Initiatives: Recent initiatives include advancing clinical trials for CFT7455 and CFT1946 and expanding its pipeline through internal discovery efforts.

Summary

C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation, an emerging therapeutic modality. While the company has a proprietary platform and growing pipeline, it faces significant risks related to clinical trial outcomes and financial sustainability. Successful development and commercialization of its drug candidates are crucial for its future success. The early stage company needs to be cognizant of potential market entry from incumbents with superior marketing, distribution, and access to capital.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • C4 Therapeutics Investor Relations
  • SEC Filings (10-K, 10-Q)
  • Company press releases
  • Financial news websites

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and may not reflect actual figures. Investment decisions should be made after consulting with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About C4 Therapeutics Inc

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2020-10-02
CEO, President & Director Mr. Andrew J. Hirsch M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 110
Full time employees 110

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.